In vitro studies support that HDC promotes cellular immunity by protecting subsets of cytotoxic lymphocytes against ROS-induced inactivation [19, 91] and that these effects of HDC are markedly enhanced by the coadministration of NK and T cell activators such as IL-2 [111]; however, complementary or alternative mechanisms are conceivable, including HDC-induced differentiation of AML cells [19, 35, 208]. The gene discussed is IL2; the disease is acute myeloid leukemia.